LydiaRx
Sovereign genomics · Governed research access · Life-sciences AI

Sovereign genomics, delivered.

We build national genomic capability inside the country that owns it. The laboratory, the data environment, the governance and the people. We make the data earn its keep for the institution that holds it. Not a single genome leaves.

A pangenome: every person's variation carried as first-class sequence, not as a deviation from someone else's genome.
EXPLORE THIS PAGE Who we are What we do In numbers Why take usseriously How it works Programmesin motion The people Questionsgovernments ask
Who we are

Your genome should not have to emigrate to be read.

78%of participants in genome-wide association studies worldwide are of European ancestry (Sirugo, Williams and Tishkoff, Cell, 2019).
1anonymous donor supplied most of the sequence of the human reference genome against which, for two decades, everyone else has been read.

Most of the world's genomic reference data describes a minority of the world's people. The countries missing from it are told, in effect, to send their samples abroad and wait. LydiaRx makes the opposite possible. A national cohort is sequenced in-country, held on infrastructure the State controls and governed to a published standard. It is then opened to the world's researchers on the country's terms. The data never moves. The revenue is shared.

We are not a sequencing vendor, a data broker or a consultancy. We are a delivery partner. We finance the first step privately, operate the secure environment, bring the research partners and hand the country a working national asset. In every country we form a local presence (a locally registered company or office, national staff and a director resident for the pilot). We are a counterpart under the country's own law, not a visitor. Our people built the programmes that others cite.

What we do

Build. Govern. Operate. Return.

We build genomic capability where the people are. And we stay there.

Build A national genome centre inside a publicinstitution (long-read laboratory, biobank,sovereign compute-to-data environment,genome portal) and a national teamtrained and certified on the full workflow. Govern The Sovereignty and Trust Charter: nosample or genome leaves; tiered,revocable consent in the nationallanguage; a national-majority DataAccess Committee; an independentGovernance and Ethics Board; twopublished audits. Operate The secure environment and theresearch gateway: every analysisapproved use by use, computedin-country, metered and logged. Partnerswork on the data without ever holding it. Return Governed research access sustains thecentre after the pilot and returns adefined share to the State under auditedterms. The pilot's findings stayroyalty-free within the public healthsystem. a programmethe countryowns
In numbers
0samples or genomes leave the country. Enforced by the platform, not promised.
3United States provisional patent applications filed in July 2026 on the custody, compute-to-data and evidence platform. Patent pending.
5Mplanned participant cohort our Board Chair designed and built as Chief Executive of Our Future Health
450kpatients sequenced in the Regeneron partnership our Scientific Chair led in Colorado
US$1bnpharmaceutical software & data programmes our Chief Executive turned round and delivered at Pfizer
6countries in active discussion across South Asia, the Gulf, the Indian Ocean, Türkiye, the Balkans and Southern Africa
Why take us seriously

Four reasons a government can check.

  • Our pilots are privately financed. No public money is needed to start one, and none of it is paid to us.
  • We cannot take the data even if we wanted to. The platform is built so that the operator is as constrained as the partner: nothing leaves, every use is on a ledger the State can verify, and a withdrawn consent is enforced by the system.
  • The people are the track record. The UK's largest health-research programme. The 100,000 Genomes Project, The Get Real Institute and Our Future Health. One of the world's largest academic–industry sequencing partnerships. A US$1 billion pharmaceutical software & data programme. Two biotechnology exits, to GSK and Novartis. All led by the people on our LydiaRx team.
  • The sequencing technology is proven at national scale. The long-read platform we specify already underpins national programmes on three continents.
How it works

How a sovereign programme works.

1 Consent in the participant'sown language, tierby tier, revocable atany time 2 Sample to a nationallaboratory in a publicinstitution; it neverleaves 3 Sequence the whole genome,long-read, bynational scientistswe train and certify 4 Hold on State-controlledservers; publish thepangenome fromnationalinfrastructure 5 Research partners bringquestions; a nationalcommittee decides;analysis runsin-country 6 Return fees and royaltiesfund the centre; ashare to the State;discoveries free athome governed research access funds the next cohort Twelve months from ethics approval to a published pangenome, a trained team and a decision on scale.
Programmes in motion

Six countries, one model.

A privately financed pilot of a few hundred long-read genomes, a national pangenome built in-country, a laboratory and secure environment that stay, a trained team, a published governance standard, and a research-access framework that pays for what comes next.

Pakistan

A 400-genome long-read pilot and the first Pakistani pangenome, sequenced entirely in Pakistan. 12–15 Pakistani scientists trained and certified. A laboratory and secure data environment that remain a national asset. All designed to lead into a one-million-genome national programme. Read more →

Proposal submitted under the Public Procurement Rules · technical team mobilised

Maldives

A sovereign cohort and the first Maldivian pangenome, sized to an island nation, with the governed-access model that makes a small cohort valuable to research partners.

In discussion

Albania

A national cohort, pangenome and in-country capability on the same model, scaled to the country and its diaspora science base.

Proposal presented

Türkiye

A 500 + 500 programme: a national long-read cohort and pangenome alongside a pathogen-genomics and surveillance pillar.

Proposal presented

Saudi Arabia

A sovereign genomics programme delivered through an in-Kingdom venture: platform, laboratory operations, scientific delivery and data governance run by LydiaRx with Saudi partners.

Design complete

South Africa

A long-read pangenome pillar and a governed-access layer proposed alongside the national genome programme, where neither yet exists.

Assessed · pillar proposal prepared
The people

Leadership and independent oversight.

Dr Andrew RoddamNajib RehmanProf. Kathleen BarnesDr Mark BaleDr Jacqueline HallJames Peach

The individuals behind LydiaRx have built the UK's largest health-research programmes, The 100,000 Genomes Project and Our Future Health, led European RWD programmes The Get Real Institute, run one of the world's largest academic–industry sequencing partnerships and US$1 billion pharmaceutical software & data programmes, and taken two biotechnology companies to acquisition by GSK and Novartis. Meet the people →

Questions governments ask
  • Who owns the data?

    The State. A public institution holds it under the Charter. A national-majority committee decides every use. LydiaRx takes no ownership of samples or data, during the pilot or after it.

  • What happens if LydiaRx disappears?

    Nothing we build depends on us staying. The laboratory, equipment and data environment are installed in the institution and offered to it; the data never left; every governance document is published; the hosting agreement provides for continuity of the platform.

  • Can researchers abroad use the data?

    Yes, by bringing their question to it. They receive governed, non-identifying results with a provenance certificate. Never a copy. The committee can refuse any request. The ledger records every one.

All the questions, and a research request step by step →

Considering a national genome programme?

Start with a briefing. It commits you to nothing. A fuller statement of capability is available to governments, institutions and funders on request.